Secondary hemophagocytic lymphohistiocytosis
MONDO:0015542Hemophagocytic lymphohistiocytosis due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.
Also known as: acquired hemophagocytic lymphohistiocytosis, acquired hemophagocytic syndrome, reactive hemophagocytic syndrome
24 clinical trials for this condition and its sub-types, 15 tagged with Secondary hemophagocytic lymphohistiocytosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Secondary hemophagocytic lymphohistiocytosis
-
Macrophage activation syndrome 13 trials
-
New drug aims to calm dangerous immune storms in Still's and lupus patients
Disease control CompletedThis study tested a drug called emapalumab in 33 children and adults with macrophage activation syndrome (MAS), a life-threatening immune overreaction, linked to Still's disease or lupus. The goal was to see if the drug could safely control the condition and reduce the need for h…
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for rare immune disease: drug combo shows promise in small study
Disease control CompletedThis study tested a combination of two drugs—interferon-gamma monoclonal antibody and dexamethasone—in 22 adults with a severe immune condition called refractory secondary HLH. The goal was to see if the treatment helps patients recover and how safe it is. Participants received t…
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug shows promise for controlling rare immune disorder
Disease control CompletedThis study tested the drug ITACITINIB in 35 adults with a mild form of a rare immune disease called HLH. The goal was to see if the drug could control the disease by improving symptoms within 15 days. The trial is now complete, and results will show how well the drug works for th…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Small study aims to unlock immune chaos in sepsis patients
Knowledge-focused CompletedThis study looked at 27 adults in intensive care to understand the inflammatory profile of macrophage activation syndrome caused by bacterial sepsis. Researchers measured specific immune markers in blood samples taken over five days. The goal is to gather knowledge that could lea…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC